The introduction of trastuzumab (Herceptin) [34], approved in 1998 and widely adopted in the early 2000s, has demonstrated particular efficacy in treating brain metastases, especially when combined with SRS, for HER2-positive breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.